CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model

Antiviral Research

Volumn 89, Issue 1, 2011, Pages 124-126

  Jiang, Tao ^a   Zhao, Hui ^a   Li, Xiao Feng ^a   Deng, Yong Qiang ^a   Liu, Juan ^a,b   Xu, Li Juan ^a   Han, Jian Feng ^a   Cao, Rui Yuan ^a   Qin, E De ^a   Qin, Cheng Feng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CpG oligodeoxynucleotide; H1N1 pandemic; Influenza A virus

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; DISEASE MODELS, ANIMAL; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VIRAL LOAD;

INFLUENZA A VIRUS; MURINAE; MUS; ORTHOMYXOVIRIDAE;

EID: 78650866475     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.11.013     Document Type: Article

References (18)

1. Ashkar A.A., Bauer S., Mitchell W.J., Vieira J., Rosenthal K.L. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 2003, 77:8948-8956.
2. Bhat A.A., Seth R.K., Kumar S., Ali R., Mohan T., Biswas S., Rao D.N. Induction of cell-mediated immune responses to peptide antigens of P. vivax in microparticles using intranasal immunization. Immunol. Invest. 2010, 39:483-499.
3. Dong L., Mori I., Hossain M.J., Liu B., Kimura Y. An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. J. Gen. Virol. 2003, 84:1623-1628.
4. Dumais N., Patrick A., Moss R.B., Davis H.L., Rosenthal K.L. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. 2002, 186:1098-1105.
5. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., Muramoto Y., Tamura D., Sakai-Tagawa Y., Noda T., Sakabe S., Imai M., Hatta Y., Watanabe S., Li C., Yamada S., Fujii K., Murakami S., Imai H., Kakugawa S., Ito M., Takano R., Iwatsuki-Horimoto K., Shimojima M., Horimoto T., Goto H., Takahashi K., Makino A., Ishigaki H., Nakayama M., Okamatsu M., Takahashi K., Warshauer D., Shult P.A., Saito R., Suzuki H., Furuta Y., Yamashita M., Mitamura K., Nakano K., Nakamura M., Brockman-Schneider R., Mitamura H., Yamazaki M., Sugaya N., Suresh M., Ozawa M., Neumann G., Gern J., Kida H., Ogasawara K., Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
6. Kamstrup S., Frimann T.H., Barfoed A.M. Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides. Antiviral Res. 2006, 72:42-48.
7. Klinman D.M. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 2006, 25:135-154.
8. Krieg A.M. Therapeutic potential of toll-like receptor 9 activation. Nat. Rev. Drug. Discov. 2006, 5:471-484.
9. Maines T.R., Jayaraman A., Belser J.A., Wadford D.A., Pappas C., Zeng H., Gustin K.M., Pearce M.B., Viswanathan K., Shriver Z.H., Raman R., Cox N.J., Sasisekharan R., Katz J.M., Tumpey T.M. Transmission and pathogenesis of swine-origin 2009 A (H1N1) influenza viruses in ferrets and mice. Science 2009, 325:484-487.
10. Norton E.B., Clements J.D., Voss T.G., Cardenas-Freytag L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J. Virol. 2010, 84:2983-2995.
11. Rees D.G., Gates A.J., Green M., Eastaugh L., Lukaszewski R.A., Griffin K.F., Krieg A.M., Titball R.W. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res. 2005, 65:87-95.
12. Schlaepfer E., Audige A., von Beust B., Manolova V., Weber M., Joller H., Bachmann M.F., Kundig T.M., Speck R.F. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J. Virol. 2004, 78:12344-12354.
13. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., Wader T., Tluk S., Liu M., Davis H.L., Krieg A.M. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004, 34:251-262.
14. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:10833-10837.
15. WHO, 2010. Pandemic (H1N1) 2009-Update 111. Available online: http://www.who.int/csr/don/2010_07_30/en/index.html.
16. WHO, 2009. Antiviral drugs for pandemic (H1N1) 2009. Available online: http://www.who.int/csr/disease/swineflu/frequently_asked_questions/antivirals/en/index.html.
17. Wong J.P., Christopher M.E., Viswanathan S., Karpoff N., Dai X., Das D., Sun L.Q., Wang M., Salazar A.M. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 2009, 27:3481-3483.
18. Wong J.P., Nagata L.P., Christopher M.E., Salazar A.M., Dale R.M. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine 2005, 23:2266-2268.